We hypothesise in this work that, as a consequence of the underlying gene network, the expression of HOXA9 could be used to stratify patients according to risk with blood cancers affecting the myeloid lineage. The gene discussed is HOXA9; the disease is hematopoietic and lymphoid system neoplasm.